Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
D'Silva, Ashley James
Dotan, Efrat
Kloth, Dwight D.
Beck, Andrew
Cohen, Steven J.
Denlinger, Crystal Shereen
机构：
[1] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
657
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.
    Mariani, Stefano
    Puzzoni, Marco
    Liscia, Nicole
    Impera, Valentino
    Pretta, Andrea
    Tolu, Simona
    Pireddu, Anna Grazia
    Persano, Mara
    Musio, Francesca
    Donisi, Clelia
    Pinna, Giovanna
    Lai, Eleonora
    Demurtas, Laura
    Ziranu, Pina
    Pusceddu, Valeria
    Pisano, Marina
    Palomba, Grazia
    Casula, Milena
    Palmieri, Giuseppe
    Scartozzi, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Nanofluidic digital PCR for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies
    Azuara, D.
    Santos, C.
    Lopez-Doriga, A.
    Montal, R.
    Sanjuan, X.
    Moreno, V.
    Tabernero, J.
    Montagut, C.
    Salazar, R.
    Capella, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S154 - S155
  • [43] Identifying prognostic subgroups for outcomes in wild-type RAS metastatic colorectal cancer (mCRC) treated with anti-EGFR drugs
    Vladimirova, L.
    Kit, O.
    Abramova, N.
    Storozhakova, A.
    Popova, I.
    Tikhanovskaya, N.
    Ezhova, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    Liu, X.
    George, G. C.
    Tsimberidou, A. M.
    Naing, A.
    Wheler, J. J.
    Kopetz, S.
    Fu, S.
    Piha-Paul, S. A.
    Eng, C.
    Falchook, G. S.
    Janku, F.
    Garrett, C.
    Karp, D.
    Kurzrock, R.
    Zinner, R.
    Raghav, K.
    Subbiah, V.
    Hess, K.
    Meric-Bernstam, F.
    Hong, D. S.
    Overman, M. J.
    BMC CANCER, 2015, 15
  • [45] Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
    Rossini, Daniele
    Germani, Marco Maria
    Pagani, Filippo
    Pellino, Antonio
    Dell'Aquila, Emanuela
    Bensi, Maria
    Liscia, Nicole
    Moretto, Roberto
    Boccaccino, Alessandra
    Prisciandaro, Michele
    Manglaviti, Sara
    Schirripa, Marta
    Vivolo, Raffaella
    Scartozzi, Mario
    Santini, Daniele
    Salvatore, Lisa
    Pietrantonio, Filippo
    Loupakis, Fotios
    Falcone, Alfredo
    Cremolini, Chiara
    CLINICAL COLORECTAL CANCER, 2020, 19 (03) : 191 - +
  • [46] Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
    X. Liu
    G. C. George
    A. M. Tsimberidou
    A. Naing
    J. J. Wheler
    S. Kopetz
    S. Fu
    S. A. Piha-Paul
    C. Eng
    G. S. Falchook
    F. Janku
    C. Garrett
    D. Karp
    R. Kurzrock
    R. Zinner
    K. Raghav
    V. Subbiah
    K. Hess
    F. Meric-Bernstam
    D. S. Hong
    M. J. Overman
    BMC Cancer, 15
  • [47] Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice
    Fedyanin, M.
    Elsnukaeva, H.
    Demidova, I.
    Stroyakovskiy, D.
    Shelygin, Y.
    Tsukanov, A.
    Panina, M.
    Moiseenko, F.
    Karpenko, E.
    Bolotina, L.
    Kudryavtseva, A.
    Filipenko, M.
    Oskorbin, I.
    Vladimirova, L. Y.
    Timoshkina, N. N.
    Kit, O. I.
    Stroganova, A.
    Dranko, S.
    Tryakin, A.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S557 - S558
  • [48] Prediction of response to anti-EGFR antibocies in metastatic colorectal cancer: looking beyond EGFR inhibition
    Ottaiano, Alessandro
    Capuozzo, Maurizio
    Nasti, Guglielmo
    Maiolino, Piera
    De Angelis, Valentina
    Scala, Stefania
    Iaffaioli, Rosario V.
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [49] Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer (mCRC)
    Manceau, G.
    Imbeaud, S.
    Mosakhani, N.
    Thiebaut, R.
    Liebaert, F.
    Van Laethem, J. L.
    Demetter, P.
    Chibaudel, B.
    Andre, T.
    Laurent-Puig, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S563 - S563
  • [50] RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies n patients with metastatic colorectal cancer (mCRC)
    Sunakawa, Y.
    Nakamura, M.
    Ishizaki, M.
    Kataoka, M.
    Satake, H.
    Kitazono, M.
    Yanagisawa, H.
    Kawamoto, Y.
    Kuramochi, H.
    Ohori, H.
    Nakamura, M.
    Takahashi, K.
    Maeda, F.
    Komeno, C.
    Takeuchi, M.
    Fujii, M.
    Yoshino, T.
    Ichikawa, W.
    Tsuji, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 114 - 114
12345